New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼ (Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
- EMEA Innovative Medicine
- New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼ (Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
New Data from the Phase 3b ESCAPE-TRD Study Show that Participants Receiving SPRAVATO®▼ (Esketamine Nasal Spray [NS]) Achieved Higher Response and Remission Rates, Increasing Over Time, Compared to those Receiving Quetiapine Extended-Release
- X (Twitter)
Copy link